Next-generation injectables : Lilly's retatrutide , a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, reported Phase 3 results in May 2026 showing 28.3% weight loss on the highest 12 mg dose at 80 weeks the largest weight loss from any approved or investigational drug in this class to date
Constipationdefined as having fewer than three bowel movements per week, hard or dry stools, or difficulty or pain with passage of stoolis a recognized adverse effect of GLP-1 receptor agonists, though it occurs less frequently than nausea or diarrhea
Shes also currently studying how collagen biostimulator treatments within three weeks of starting the first dose of GLP-1s can help patients get weight loss without the face loss
BDNF promotes the survival of existing neurons, encourages the growth of new synaptic connections, and supports the process of neurogenesis in the hippocampus, the brain region most critical for memory formation and one of the first affected in Alzheimer's disease [17]